Chardan Capital reiterated their neutral rating on shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) in a research report released on Friday morning, Benzinga reports. Chardan Capital currently has a $2.00 price target on the biopharmaceutical company’s stock. PRQR has been the subject of several other reports. StockNews.com cut ProQR Therapeutics from a buy rating […]
Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk. Profitability This table compares ProQR Therapeutics and […]
Shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) have been given a consensus rating of “Moderate Buy” by the five research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month […]